PEMAZYRE dosing and administration — 1 of 5

PEMAZYRE is a once-daily oral therapy

PEMAZYRE is taken on a 21-day cycle, with 14 days on treatment (once daily), followed by 7 days without treatment1

The recommended dosage of PEMAZYRE is 13.5 mg taken orally once daily on a 21-day treatment cycle1

blue circle blue circle blue circle blue circle blue circle blue circle blue circle
blue circle blue circle blue circle blue circle blue circle blue circle blue circle

14 days of once-daily therapy

orange cross orange cross orange cross orange cross orange cross orange cross orange cross

7 days of no therapy

Continue treatment until disease progression or unacceptable toxicity occurs1

Therapy should be initiated by a physician experienced in the diagnosis and treatment of patients with BTC1

FGFR2 fusion positivity status must be known prior to initiation of PEMAZYRE therapy. Assessment for FGFR2 fusion positivity in tumour specimens should be performed with an appropriate diagnostic test1


For further information, please refer to the PEMAZYRE Summary of Product Characteristics.1